In several senior roles, Ian has gained considerable experience and understanding of research and development and licensing activities, with an extensive network of contacts throughout the pharmaceutical, biotech, and VC communities. He has demonstrated the ability to maintain vision and strategy while managing teams through complex internal and external situations. Ian has an in-depth knowledge and understanding of drug development, regulatory guidelines, and commercial valuation. He has been responsible for approvals and transitioning of many compounds through various phases of research and development.

In Licensing roles in LEO, Bayer, and Novartis, Ian had responsibility for the development input for BD&L activities in all therapeutic areas globally. He was directly involved in numerous successful in-licensing deals, Ian also served on the Joint Development Committee for a small biotech company that had an option agreement with Novartis. He was also a member of the Novartis/MPM Venture Capital Joint Venture assessment team, looking at innovative new product concepts in multiple therapeutic areas.